LASERSIGHT LASERSCAN LSX EXCIMER LASER SYSTEM FOR LASER-ASSITED IN SITU KERATOMILEUSIS (LASIK)

Excimer Laser System

FDA Premarket Approval P980008 S005

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for the lasersight laserscan lsx excimer laser system for laser-assisted in situ keratomileusis (lasik). The device is indicated for lasik: 1) for the reduction or elimination of myopia ranging from -0. 5 to less than -6. 0 diopters (d) spherical equivalent, with astigmatism less than or equal to 4. 5 d, as measured at the spectacle plane; 2) in patients with documentation of a stable manifest refraction defined as

DeviceLASERSIGHT LASERSCAN LSX EXCIMER LASER SYSTEM FOR LASER-ASSITED IN SITU KERATOMILEUSIS (LASIK)
Classification NameExcimer Laser System
Generic NameExcimer Laser System
ApplicantLASERSIGHT TECHNOLOGIES, INC.
Date Received2000-12-19
Decision Date2001-09-28
Notice Date2001-10-26
PMAP980008
SupplementS005
Product CodeLZS
Docket Number01M-0490
Advisory CommitteeOphthalmic
Supplement TypePanel Track
Supplement ReasonLabeling Change - Indications/instructions/shelf Life/tradename
Expedited ReviewNo
Combination Product No
Applicant Address LASERSIGHT TECHNOLOGIES, INC. 6903 University Blvd., winter Park, FL 32792
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P980008Original Filing
S012 2002-10-31 Real-time Process
S011
S010
S009 2001-10-26 Special (immediate Track)
S008 2001-10-05 Real-time Process
S007
S006
S005 2000-12-19 Panel Track
S004
S003 2000-07-20 Real-time Process
S002 2000-07-13 Normal 180 Day Track
S001

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.